-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Reiterates Buy on Trevi Therapeutics, Raises Price Target to $20

Benzinga·03/19/2025 15:51:51
Listen to the news
B. Riley Securities analyst Mayank Mamtani reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and raises the price target from $11 to $20.